Panacea Acquisition Corporation (PANA) Shareholders Approve Nuvation Bio Deal
Panacea Acquisition Corporation (NYSE:PANA) announced that its shareholders have approved its combination with drug developer Nuvation Bio at a special meeting earlier today.
No redemption information was given. The vote results were ~94% in favor of the combination with ~6% voting against the merger, with 500 shares abstaining. ...READ MORE
